Lung Cancer CA209-9LA

A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease

Eligibility Criteria:

  1. Participants with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy.
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
  3. Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria.
  4. Participants must have PD-L1 IHC testing with results performed by a central laboratory during the screening period

This study is for patients age 18 and older.

Available at: Hospital of Central Connecticut